Lixmabegagene relduparvovec

N/A

Report date: 2023/10/26 17:00:07

Base Information

Drug NameLixmabegagene relduparvovec
Drug Alias NameLYS-GM101LYS-GM-101
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh10 vector
Mechanisms of ActionGene transferenceBeta-galactosidase modulators
TargetsBeta-galactosidase
Therapy Area/IndicationsGangliosidosis, GM1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLysogene
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLysogene
Active IndicationsN/A
Inactive IndicationsGangliosidosis, GM1

Other Information

ATC CodeN/A
Related LinksN/A